1700 Owens Street, Suite 595,
San Francisco, California 94158
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on the preventive treatment of migraine. Labrys’ lead candidate, LBR-101 (formerly RN-307), is an anti-CGRP monoclonal antibody for the prevention of chronic and high frequency migraine currently in Phase 2b clinical development
Labrys Biologics was acquired by Teva Pharmaceutical Industries on June 03, 2014.
Join Mergr to view all 208 acquisitions of life science companies in 2014, including 13 acquisitions by private equity firms, and 195 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 12 in number of deals in 2014. The largest life science acquisition in 2014 was InterMune - which was acquired by Roche Holding AG for $8.3B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Labrys Biologics.
No obligation. Cancel anytime.